Nvision Biomedical Technologies, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$773Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
119clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Foot and Ankle $90K associated (2023-2025)
- Trigon $24K associated (2023-2025)
- Javelin $22K associated (2023-2025)
- Healix $12K associated (2023-2025)
- Vector $7,112 associated (2023-2025)
- Focus $5,264 associated (2023-2025)
- Spine $5,048 associated (2023-2025)
- Ankle Wedge $2,067 associated (2023-2025)
- Radian $602 associated (2023-2025)
- Foot & Ankle Device $153 associated (2023-2025)
- Boundary $148 associated (2023-2025)
- Food and Ankle $22.20 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Brandon Lampe | Mesquite, TX | Podiatrist | $150,297.60 |
| Binoy Sheth | Allen, TX | Podiatrist | $116,000.00 |
| Christopher Happ | Weatherford, TX | Orthopaedic Surgery of The Spine | $93,890.47 |
| David Yeager | Morrison, IL | Podiatrist | $67,051.10 |
| Larry Kjeldgaard | Hurst, TX | Orthopaedic Surgery | $34,500.00 |
| Brian Dix | Sioux Falls, SD | Podiatrist | $26,308.36 |
| Matthew Lining | Carmel, IN | Foot & Ankle Surgery | $23,718.94 |
| Walter Strash | San Antonio, TX | Foot & Ankle Surgery | $21,004.81 |
| Jesse Wolfe | Saint Louis, MO | Foot & Ankle Surgery | $20,089.11 |
| Toritsenere Onosode | Frisco, TX | Foot & Ankle Surgery | $19,097.94 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.